Association between genetic polymorphisms of CYP2d6 and outcomes in breast cancer patients with tamoxifen treatment

Hyung Seok Park, Ji Yeob Choi, Mi Jeong Lee, Seho Park, Chang Woo Yeo, Sang Seop Lee, Jae Gook Shin, Byeongwoo Park

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The aim of the study was to evaluate the association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. We evaluated the CYP2D6 genetic polymorphisms in 766 breast cancer patients. Among them, 110 patients whose samples were prospectively collected before surgery and treated with tamoxifen were included to evaluate the association between CYP2D6 and outcomes. The genotypes of CYP2D6 were categorized as extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) according to the activity score. The clinicopathologic features of 110 patients were not significantly different among the three groups except for the T-stage and nodal status. The high T-stage and axillary metastasis were more frequent in the PM group. While recurrence-free and overall survival in the PM group was poorer than the other groups, there was no significant difference between the EM and the IM group. The difference between the PM and the other groups on univariate analysis disappeared on multivariate analysis. These conflicting results suggest that the clinical value of CYP2D6 polymorphisms is still unclear and more large-sized and comprehensively designed trials are necessary.

Original languageEnglish
Pages (from-to)1007-1013
Number of pages7
JournalJournal of Korean medical science
Volume26
Issue number8
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

Cytochrome P-450 CYP2D6
Genetic Polymorphisms
Tamoxifen
Breast Neoplasms
Therapeutics
Multivariate Analysis
Genotype
Neoplasm Metastasis
Recurrence
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Park, Hyung Seok ; Choi, Ji Yeob ; Lee, Mi Jeong ; Park, Seho ; Yeo, Chang Woo ; Lee, Sang Seop ; Shin, Jae Gook ; Park, Byeongwoo. / Association between genetic polymorphisms of CYP2d6 and outcomes in breast cancer patients with tamoxifen treatment. In: Journal of Korean medical science. 2011 ; Vol. 26, No. 8. pp. 1007-1013.
@article{2fb3a79d9df745caa3aa44e703ffa111,
title = "Association between genetic polymorphisms of CYP2d6 and outcomes in breast cancer patients with tamoxifen treatment",
abstract = "The aim of the study was to evaluate the association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. We evaluated the CYP2D6 genetic polymorphisms in 766 breast cancer patients. Among them, 110 patients whose samples were prospectively collected before surgery and treated with tamoxifen were included to evaluate the association between CYP2D6 and outcomes. The genotypes of CYP2D6 were categorized as extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) according to the activity score. The clinicopathologic features of 110 patients were not significantly different among the three groups except for the T-stage and nodal status. The high T-stage and axillary metastasis were more frequent in the PM group. While recurrence-free and overall survival in the PM group was poorer than the other groups, there was no significant difference between the EM and the IM group. The difference between the PM and the other groups on univariate analysis disappeared on multivariate analysis. These conflicting results suggest that the clinical value of CYP2D6 polymorphisms is still unclear and more large-sized and comprehensively designed trials are necessary.",
author = "Park, {Hyung Seok} and Choi, {Ji Yeob} and Lee, {Mi Jeong} and Seho Park and Yeo, {Chang Woo} and Lee, {Sang Seop} and Shin, {Jae Gook} and Byeongwoo Park",
year = "2011",
month = "8",
day = "1",
doi = "10.3346/jkms.2011.26.8.1007",
language = "English",
volume = "26",
pages = "1007--1013",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "8",

}

Association between genetic polymorphisms of CYP2d6 and outcomes in breast cancer patients with tamoxifen treatment. / Park, Hyung Seok; Choi, Ji Yeob; Lee, Mi Jeong; Park, Seho; Yeo, Chang Woo; Lee, Sang Seop; Shin, Jae Gook; Park, Byeongwoo.

In: Journal of Korean medical science, Vol. 26, No. 8, 01.08.2011, p. 1007-1013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between genetic polymorphisms of CYP2d6 and outcomes in breast cancer patients with tamoxifen treatment

AU - Park, Hyung Seok

AU - Choi, Ji Yeob

AU - Lee, Mi Jeong

AU - Park, Seho

AU - Yeo, Chang Woo

AU - Lee, Sang Seop

AU - Shin, Jae Gook

AU - Park, Byeongwoo

PY - 2011/8/1

Y1 - 2011/8/1

N2 - The aim of the study was to evaluate the association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. We evaluated the CYP2D6 genetic polymorphisms in 766 breast cancer patients. Among them, 110 patients whose samples were prospectively collected before surgery and treated with tamoxifen were included to evaluate the association between CYP2D6 and outcomes. The genotypes of CYP2D6 were categorized as extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) according to the activity score. The clinicopathologic features of 110 patients were not significantly different among the three groups except for the T-stage and nodal status. The high T-stage and axillary metastasis were more frequent in the PM group. While recurrence-free and overall survival in the PM group was poorer than the other groups, there was no significant difference between the EM and the IM group. The difference between the PM and the other groups on univariate analysis disappeared on multivariate analysis. These conflicting results suggest that the clinical value of CYP2D6 polymorphisms is still unclear and more large-sized and comprehensively designed trials are necessary.

AB - The aim of the study was to evaluate the association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. We evaluated the CYP2D6 genetic polymorphisms in 766 breast cancer patients. Among them, 110 patients whose samples were prospectively collected before surgery and treated with tamoxifen were included to evaluate the association between CYP2D6 and outcomes. The genotypes of CYP2D6 were categorized as extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) according to the activity score. The clinicopathologic features of 110 patients were not significantly different among the three groups except for the T-stage and nodal status. The high T-stage and axillary metastasis were more frequent in the PM group. While recurrence-free and overall survival in the PM group was poorer than the other groups, there was no significant difference between the EM and the IM group. The difference between the PM and the other groups on univariate analysis disappeared on multivariate analysis. These conflicting results suggest that the clinical value of CYP2D6 polymorphisms is still unclear and more large-sized and comprehensively designed trials are necessary.

UR - http://www.scopus.com/inward/record.url?scp=80052665548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052665548&partnerID=8YFLogxK

U2 - 10.3346/jkms.2011.26.8.1007

DO - 10.3346/jkms.2011.26.8.1007

M3 - Article

VL - 26

SP - 1007

EP - 1013

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 8

ER -